CA2208672C - Immunotherapeutic imides/amides and their use for reducing levels of tnf.alpha. - Google Patents
Immunotherapeutic imides/amides and their use for reducing levels of tnf.alpha. Download PDFInfo
- Publication number
- CA2208672C CA2208672C CA002208672A CA2208672A CA2208672C CA 2208672 C CA2208672 C CA 2208672C CA 002208672 A CA002208672 A CA 002208672A CA 2208672 A CA2208672 A CA 2208672A CA 2208672 C CA2208672 C CA 2208672C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutical composition
- phthalimido
- carbon atoms
- dimethoxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000003949 imides Chemical class 0.000 title abstract description 5
- 150000001408 amides Chemical class 0.000 title description 3
- 230000001024 immunotherapeutic effect Effects 0.000 title description 2
- -1 amide ethers Chemical class 0.000 claims abstract description 21
- 230000010076 replication Effects 0.000 claims abstract description 16
- 241001430294 unidentified retrovirus Species 0.000 claims abstract description 13
- KVMCPRAFESVWBU-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-1-hydroxypropyl]isoindole-1,3-dione Chemical group O=C1C2=CC=CC=C2C(=O)N1C(O)(CC)C1=CC=C(OC)C(OC)=C1 KVMCPRAFESVWBU-UHFFFAOYSA-N 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 73
- 239000008194 pharmaceutical composition Substances 0.000 claims description 41
- 125000004432 carbon atom Chemical group C* 0.000 claims description 31
- 241000124008 Mammalia Species 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 8
- 125000001475 halogen functional group Chemical group 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- NIRRAUQSXSIQCM-UHFFFAOYSA-N 2-(1-cyclohexyl-3-methoxypropyl)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C(CCOC)C1CCCCC1 NIRRAUQSXSIQCM-UHFFFAOYSA-N 0.000 claims description 2
- SURVJBLCJYZARJ-UHFFFAOYSA-N 2-[1-(3,4-diethoxyphenyl)-3-(pyridin-3-ylmethoxy)propyl]-3h-isoindol-1-one Chemical compound C1=C(OCC)C(OCC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CCOCC1=CC=CN=C1 SURVJBLCJYZARJ-UHFFFAOYSA-N 0.000 claims description 2
- ABWKQRZAXZSENY-UHFFFAOYSA-N 2-[1-(3,4-diethoxyphenyl)-3-(pyridin-3-ylmethoxy)propyl]isoindole-1,3-dione Chemical compound C1=C(OCC)C(OCC)=CC=C1C(N1C(C2=CC=CC=C2C1=O)=O)CCOCC1=CC=CN=C1 ABWKQRZAXZSENY-UHFFFAOYSA-N 0.000 claims description 2
- YZVHNZUSOUUPIF-UHFFFAOYSA-N 2-[1-(3,4-diethoxyphenyl)-3-ethoxypropyl]-3h-isoindol-1-one Chemical compound C1C2=CC=CC=C2C(=O)N1C(CCOCC)C1=CC=C(OCC)C(OCC)=C1 YZVHNZUSOUUPIF-UHFFFAOYSA-N 0.000 claims description 2
- OBKIJVASAALGIC-UHFFFAOYSA-N 2-[1-(3,4-diethoxyphenyl)-3-ethoxypropyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C(CCOCC)C1=CC=C(OCC)C(OCC)=C1 OBKIJVASAALGIC-UHFFFAOYSA-N 0.000 claims description 2
- ZULPTSGAYKJABC-UHFFFAOYSA-N 2-[1-(3,4-diethoxyphenyl)-3-hydroxypropyl]-3h-isoindol-1-one Chemical compound C1=C(OCC)C(OCC)=CC=C1C(CCO)N1C(=O)C2=CC=CC=C2C1 ZULPTSGAYKJABC-UHFFFAOYSA-N 0.000 claims description 2
- XQZNJHAYSAQMTC-UHFFFAOYSA-N 2-[1-(3,4-diethoxyphenyl)-3-hydroxypropyl]isoindole-1,3-dione Chemical compound C1=C(OCC)C(OCC)=CC=C1C(CCO)N1C(=O)C2=CC=CC=C2C1=O XQZNJHAYSAQMTC-UHFFFAOYSA-N 0.000 claims description 2
- CLMCKJZPPDFVJP-UHFFFAOYSA-N 2-[1-(3,4-diethoxyphenyl)-3-methoxypropyl]-3h-isoindol-1-one Chemical compound C1=C(OCC)C(OCC)=CC=C1C(CCOC)N1C(=O)C2=CC=CC=C2C1 CLMCKJZPPDFVJP-UHFFFAOYSA-N 0.000 claims description 2
- BIUXHKWMYCCXFD-UHFFFAOYSA-N 2-[1-(3,4-diethoxyphenyl)-3-methoxypropyl]isoindole-1,3-dione Chemical compound C1=C(OCC)C(OCC)=CC=C1C(CCOC)N1C(=O)C2=CC=CC=C2C1=O BIUXHKWMYCCXFD-UHFFFAOYSA-N 0.000 claims description 2
- PKUCGQFSYKQYTA-UHFFFAOYSA-N 2-[1-(3,4-diethylphenyl)-3-hydroxypropyl]-3h-isoindol-1-one Chemical compound C1=C(CC)C(CC)=CC=C1C(CCO)N1C(=O)C2=CC=CC=C2C1 PKUCGQFSYKQYTA-UHFFFAOYSA-N 0.000 claims description 2
- LEMRBPKYXRBPMS-UHFFFAOYSA-N 2-[1-(3,4-diethylphenyl)-3-hydroxypropyl]isoindole-1,3-dione Chemical compound C1=C(CC)C(CC)=CC=C1C(CCO)N1C(=O)C2=CC=CC=C2C1=O LEMRBPKYXRBPMS-UHFFFAOYSA-N 0.000 claims description 2
- FMGSEHXVDZYZTR-UHFFFAOYSA-N 2-[1-(3,4-diethylphenyl)-3-methoxypropyl]-3h-isoindol-1-one Chemical compound C1=C(CC)C(CC)=CC=C1C(CCOC)N1C(=O)C2=CC=CC=C2C1 FMGSEHXVDZYZTR-UHFFFAOYSA-N 0.000 claims description 2
- PEQDKCNUZDVHQV-UHFFFAOYSA-N 2-[1-(3,4-diethylphenyl)-3-methoxypropyl]isoindole-1,3-dione Chemical compound C1=C(CC)C(CC)=CC=C1C(CCOC)N1C(=O)C2=CC=CC=C2C1=O PEQDKCNUZDVHQV-UHFFFAOYSA-N 0.000 claims description 2
- IVLHPAQFBYWEJU-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-2-hydroxyethyl]-3h-isoindol-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(CO)N1C(=O)C2=CC=CC=C2C1 IVLHPAQFBYWEJU-UHFFFAOYSA-N 0.000 claims description 2
- QXAGUSKCPCOMFS-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-2-methoxyethyl]-3h-isoindol-1-one Chemical compound C1C2=CC=CC=C2C(=O)N1C(COC)C1=CC=C(OC)C(OC)=C1 QXAGUSKCPCOMFS-UHFFFAOYSA-N 0.000 claims description 2
- UWBVXCHUKULWAX-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-2-methoxyethyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C(COC)C1=CC=C(OC)C(OC)=C1 UWBVXCHUKULWAX-UHFFFAOYSA-N 0.000 claims description 2
- DMBIWHRHUANOQN-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-3-(pyridin-3-ylmethoxy)propyl]-3h-isoindol-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(N1C(C2=CC=CC=C2C1)=O)CCOCC1=CC=CN=C1 DMBIWHRHUANOQN-UHFFFAOYSA-N 0.000 claims description 2
- NAGKNLYKRHXBBC-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-3-(pyridin-3-ylmethoxy)propyl]isoindole-1,3-dione Chemical compound C1=C(OC)C(OC)=CC=C1C(N1C(C2=CC=CC=C2C1=O)=O)CCOCC1=CC=CN=C1 NAGKNLYKRHXBBC-UHFFFAOYSA-N 0.000 claims description 2
- GXVUEMYFPGQBQF-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-3-ethoxypropyl]-3h-isoindol-1-one Chemical compound C1C2=CC=CC=C2C(=O)N1C(CCOCC)C1=CC=C(OC)C(OC)=C1 GXVUEMYFPGQBQF-UHFFFAOYSA-N 0.000 claims description 2
- PXYNITJRLDAHOM-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-3-ethoxypropyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C(CCOCC)C1=CC=C(OC)C(OC)=C1 PXYNITJRLDAHOM-UHFFFAOYSA-N 0.000 claims description 2
- JWJVWOATGIGNEO-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-3-hydroxypropyl]-3h-isoindol-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(CCO)N1C(=O)C2=CC=CC=C2C1 JWJVWOATGIGNEO-UHFFFAOYSA-N 0.000 claims description 2
- NTWLARBDJFXJNZ-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-3-hydroxypropyl]isoindole-1,3-dione Chemical compound C1=C(OC)C(OC)=CC=C1C(CCO)N1C(=O)C2=CC=CC=C2C1=O NTWLARBDJFXJNZ-UHFFFAOYSA-N 0.000 claims description 2
- QRYPKORMUWBUPW-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-3-methoxypropyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C(CCOC)C1=CC=C(OC)C(OC)=C1 QRYPKORMUWBUPW-UHFFFAOYSA-N 0.000 claims description 2
- KCWUSICDMKMHLA-UHFFFAOYSA-N 2-[1-(3,4-dipropylphenyl)-3-hydroxypropyl]-3h-isoindol-1-one Chemical compound C1=C(CCC)C(CCC)=CC=C1C(CCO)N1C(=O)C2=CC=CC=C2C1 KCWUSICDMKMHLA-UHFFFAOYSA-N 0.000 claims description 2
- DBWODBMGDKIQOM-UHFFFAOYSA-N 2-[1-(3,4-dipropylphenyl)-3-hydroxypropyl]isoindole-1,3-dione Chemical compound C1=C(CCC)C(CCC)=CC=C1C(CCO)N1C(=O)C2=CC=CC=C2C1=O DBWODBMGDKIQOM-UHFFFAOYSA-N 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Substances 0.000 claims description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000005724 cycloalkenylene group Chemical group 0.000 claims description 2
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims 3
- WGPJSGUADVYEMG-UHFFFAOYSA-N 2-[1-(3,4-diethylcyclohexyl)-3-methoxypropyl]isoindole-1,3-dione Chemical compound C1C(CC)C(CC)CCC1C(CCOC)N1C(=O)C2=CC=CC=C2C1=O WGPJSGUADVYEMG-UHFFFAOYSA-N 0.000 claims 1
- CFGVKYUFXMMFEN-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-2-hydroxyethyl]isoindole-1,3-dione Chemical compound C1=C(OC)C(OC)=CC=C1C(CO)N1C(=O)C2=CC=CC=C2C1=O CFGVKYUFXMMFEN-UHFFFAOYSA-N 0.000 claims 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- JNYZKRQUOLHBJO-UHFFFAOYSA-N O=C1N(CC2=CC=CC=C12)C(CCOC)C1=CC(=C(C=C1)OC)OC Chemical compound O=C1N(CC2=CC=CC=C12)C(CCOC)C1=CC(=C(C=C1)OC)OC JNYZKRQUOLHBJO-UHFFFAOYSA-N 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 abstract description 6
- 206010006895 Cachexia Diseases 0.000 abstract description 5
- 206010014824 Endotoxic shock Diseases 0.000 abstract description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 2
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 1
- 108700012920 TNF Proteins 0.000 description 48
- 239000004480 active ingredient Substances 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 241000725303 Human immunodeficiency virus Species 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 239000000203 mixture Substances 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 208000030507 AIDS Diseases 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 208000031886 HIV Infections Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 208000037357 HIV infectious disease Diseases 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- 101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 3
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 3
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 208000001388 Opportunistic Infections Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000019664 bone resorption disease Diseases 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000007302 negative regulation of cytokine production Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002947 procoagulating effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108091006106 transcriptional activators Proteins 0.000 description 2
- 229940100445 wheat starch Drugs 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LIVKGYIUNICCIZ-UHFFFAOYSA-N 3-amino-3-(3,4-dimethoxyphenyl)propan-1-ol Chemical compound COC1=CC=C(C(N)CCO)C=C1OC LIVKGYIUNICCIZ-UHFFFAOYSA-N 0.000 description 1
- FGCXSFRGPCUBPW-UHFFFAOYSA-N 3-amino-3-(3,4-dimethoxyphenyl)propanoic acid Chemical compound COC1=CC=C(C(N)CC(O)=O)C=C1OC FGCXSFRGPCUBPW-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- YYDXWNZZLPCQSL-UHFFFAOYSA-N CC1CC(C)=CC1 Chemical compound CC1CC(C)=CC1 YYDXWNZZLPCQSL-UHFFFAOYSA-N 0.000 description 1
- RHVQCDLIBLNXQW-WHXUTIOJSA-N CCCCC1(CC(C)[C@@H](C)C1)N Chemical compound CCCCC1(CC(C)[C@@H](C)C1)N RHVQCDLIBLNXQW-WHXUTIOJSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 206010010755 Conjunctivitis viral Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 101100229963 Drosophila melanogaster grau gene Proteins 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010020164 HIV infection CDC Group III Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102100026966 Thrombomodulin Human genes 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 208000005914 Viral Conjunctivitis Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000713325 Visna/maedi virus Species 0.000 description 1
- 102100029477 Vitamin K-dependent protein C Human genes 0.000 description 1
- 101710193900 Vitamin K-dependent protein C Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 108010009896 bone resorption factor Proteins 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000005796 circulatory shock Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- VRHAQNTWKSVEEC-UHFFFAOYSA-N ethyl 1,3-dioxoisoindole-2-carboxylate Chemical compound C1=CC=C2C(=O)N(C(=O)OCC)C(=O)C2=C1 VRHAQNTWKSVEEC-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000009791 fibrotic reaction Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-N methoxyacetic acid Chemical compound COCC(O)=O RMIODHQZRUFFFF-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000020046 sherry Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36666794A | 1994-12-30 | 1994-12-30 | |
| US08/366,677 | 1994-12-30 | ||
| PCT/US1995/015119 WO1996020705A1 (en) | 1994-12-30 | 1995-11-20 | IMMUNOTHERAPEUTIC IMIDES/AMIDES AND THEIR USE FOR REDUCING LEVELS OF TNF$g(a) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2208672A1 CA2208672A1 (en) | 1996-07-11 |
| CA2208672C true CA2208672C (en) | 2008-02-12 |
Family
ID=23443993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002208672A Expired - Fee Related CA2208672C (en) | 1994-12-30 | 1995-11-20 | Immunotherapeutic imides/amides and their use for reducing levels of tnf.alpha. |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0797437B1 (cs) |
| JP (1) | JPH10511678A (cs) |
| AT (1) | ATE200621T1 (cs) |
| AU (1) | AU696817B2 (cs) |
| CA (1) | CA2208672C (cs) |
| CZ (1) | CZ290372B6 (cs) |
| DE (1) | DE69520750T2 (cs) |
| DK (1) | DK0797437T3 (cs) |
| ES (1) | ES2155537T3 (cs) |
| FI (1) | FI972708A7 (cs) |
| GR (1) | GR3036131T3 (cs) |
| HU (1) | HU226558B1 (cs) |
| NZ (1) | NZ296925A (cs) |
| PL (1) | PL185101B1 (cs) |
| PT (1) | PT797437E (cs) |
| RU (1) | RU2164514C2 (cs) |
| SK (1) | SK86997A3 (cs) |
| WO (1) | WO1996020705A1 (cs) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5658940A (en) * | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
| DE69700616T2 (de) * | 1996-07-02 | 2000-03-16 | Nisshin Flour Milling Co., Ltd. | Imid derivate |
| EP1661566A3 (en) * | 1996-08-05 | 2008-04-16 | Myriad Genetics, Inc. | Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors |
| AU732174B2 (en) * | 1996-08-05 | 2001-04-12 | Myriad Genetics, Inc. | Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors |
| US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| WO2002064093A2 (en) | 2001-02-15 | 2002-08-22 | King Pharmaceuticals, Inc. | Stabilized pharmaceutical and thyroid hormone compositions and method of preparation |
| US7320991B2 (en) | 2001-02-27 | 2008-01-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Analogs of thalidomide as potential angiogenesis inhibitors |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US8952895B2 (en) | 2011-06-03 | 2015-02-10 | Apple Inc. | Motion-based device operations |
| US7973057B2 (en) | 2003-09-17 | 2011-07-05 | The United States Of America As Represented By The Department Of Health And Human Services | Thalidomide analogs |
| US8927725B2 (en) | 2011-12-02 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thio compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4467097A (en) * | 1982-09-29 | 1984-08-21 | General Electric Company | Method for making aromatic bis(etherimide)s |
| AU1531492A (en) * | 1991-02-14 | 1992-09-15 | Rockefeller University, The | Method for controlling abnormal concentration tnf alpha in human tissues |
| US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
-
1995
- 1995-11-20 CZ CZ19972035A patent/CZ290372B6/cs not_active IP Right Cessation
- 1995-11-20 WO PCT/US1995/015119 patent/WO1996020705A1/en not_active Ceased
- 1995-11-20 ES ES95940063T patent/ES2155537T3/es not_active Expired - Lifetime
- 1995-11-20 RU RU97112903/04A patent/RU2164514C2/ru not_active IP Right Cessation
- 1995-11-20 PT PT95940063T patent/PT797437E/pt unknown
- 1995-11-20 FI FI972708A patent/FI972708A7/fi unknown
- 1995-11-20 DE DE69520750T patent/DE69520750T2/de not_active Expired - Fee Related
- 1995-11-20 AU AU41667/96A patent/AU696817B2/en not_active Ceased
- 1995-11-20 NZ NZ296925A patent/NZ296925A/en unknown
- 1995-11-20 HU HU9701842A patent/HU226558B1/hu not_active IP Right Cessation
- 1995-11-20 EP EP95940063A patent/EP0797437B1/en not_active Expired - Lifetime
- 1995-11-20 JP JP8520977A patent/JPH10511678A/ja active Pending
- 1995-11-20 CA CA002208672A patent/CA2208672C/en not_active Expired - Fee Related
- 1995-11-20 DK DK95940063T patent/DK0797437T3/da active
- 1995-11-20 AT AT95940063T patent/ATE200621T1/de not_active IP Right Cessation
- 1995-11-20 PL PL95321071A patent/PL185101B1/pl not_active IP Right Cessation
- 1995-11-20 SK SK869-97A patent/SK86997A3/sk unknown
-
2001
- 2001-06-27 GR GR20010400984T patent/GR3036131T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69520750D1 (de) | 2001-05-23 |
| DE69520750T2 (de) | 2001-09-13 |
| AU4166796A (en) | 1996-07-24 |
| PL185101B1 (pl) | 2003-02-28 |
| FI972708A0 (fi) | 1997-06-23 |
| HU226558B1 (en) | 2009-03-30 |
| EP0797437B1 (en) | 2001-04-18 |
| JPH10511678A (ja) | 1998-11-10 |
| NZ296925A (en) | 1998-06-26 |
| FI972708L (fi) | 1997-08-29 |
| AU696817B2 (en) | 1998-09-17 |
| CA2208672A1 (en) | 1996-07-11 |
| FI972708A7 (fi) | 1997-08-29 |
| ES2155537T3 (es) | 2001-05-16 |
| DK0797437T3 (da) | 2001-06-05 |
| GR3036131T3 (en) | 2001-09-28 |
| PT797437E (pt) | 2001-07-31 |
| SK86997A3 (en) | 1998-01-14 |
| RU2164514C2 (ru) | 2001-03-27 |
| HUT77978A (hu) | 1999-01-28 |
| CZ290372B6 (cs) | 2002-07-17 |
| WO1996020705A1 (en) | 1996-07-11 |
| ATE200621T1 (de) | 2001-05-15 |
| EP0797437A1 (en) | 1997-10-01 |
| CZ203597A3 (en) | 1997-11-12 |
| PL321071A1 (en) | 1997-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5703098A (en) | Immunotherapeutic imides/amides | |
| EP0800505B1 (en) | Novel immunotherapeutic aryl amides | |
| EP1004572B1 (en) | Amines as inhibitors of TNF alpha | |
| US5658940A (en) | Succinimide and maleimide cytokine inhibitors | |
| US6844359B2 (en) | Substituted imides | |
| US5728845A (en) | Immunotherapeutic nitriles | |
| WO1996020926A9 (en) | Substituted imides as tnf inhibitors | |
| CA2208672C (en) | Immunotherapeutic imides/amides and their use for reducing levels of tnf.alpha. | |
| KR100496308B1 (ko) | 면역요법용 이미드/아미드 및 ＴＮＦα의 레벨을감소시키는 이의 용도 | |
| HK1025765B (en) | Amines as inhibitors of tnf alpha | |
| HK1017885B (en) | Succinimide and maleimide cytokine inhibitors | |
| HK1022692B (en) | Inhibitors of tumor necrosis factor alpha |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |